UroGen Pharma drops on Q3 miss

UroGen Pharma

15/11/2021 16:13

** U.S. shares of Israeli drug developer  URGN.O  down 12.3%
to $16.76
    ** Co posts Q3 net loss of $1.35 per share versus estimates
of a $1.29/shr loss; revenue of $11.35 mln also missed
expectations of $15.4 mln - Refinitiv data   urn:newsml:reuters.com:*:nBw65DpNVa
    ** URGN forecast FY21 revenue between $47 mln and $51 mln;
analysts on average expect $54.5 mln
    ** On Nov. 10, co said following discussions with the U.S.
FDA, it has ceased enrollment in late-stage study testing its
experimental cancer treatment, UGN-102, and plans to initiate a
new study of the therapy in early 2022
    ** Including session's losses, stock down ~7% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))